Patents by Inventor Jingwu Z. Zang

Jingwu Z. Zang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Isolation and identification of cross-reactive T cells
    Patent number: 7972848
    Abstract: Cross-reactive T cells recognizing both MBP93-105 and HHV-61-13 peptides represent a significant subset of T cells with some degree of TCR degeneracy. It appears that the recognition of the cross-reactive T cells has a less stringent requirement for the flanking residues of the two peptides. In contrast, these flanking residues are critical for the T cell recognition of mono-specific T cells. The association between HHV-6 and autoreactive immune responses to MBP indicates that cross-reactive T cells, peptides from the V-D-J region of the T cell receptor from autoreactive T cells, and antiviral agents may prevent or treat MS.
    Type: Grant
    Filed: August 19, 2009
    Date of Patent: July 5, 2011
    Assignee: Opexa Therapeutics, Inc.
    Inventor: Jingwu Z. Zang
  • T Cell Receptor CDR3 Sequences and Methods for Detection
    Publication number: 20100291123
    Abstract: The present invention relates generally to the field of treating autoimmune diseases, such as multiple sclerosis (MS), rheumatoid arthritis (RA) and others. Methods of treating and monitoring an autoimmune disease by utilizing T-cell receptors peptides are disclosed. Nucleic acid and peptide sequences of T-cell receptors found in a population of MS patients are also disclosed.
    Type: Application
    Filed: May 11, 2010
    Publication date: November 18, 2010
    Applicant: Baylor College of Medicine
    Inventor: Jingwu Z. Zang
  • Isolation and Identification of T Cells
    Publication number: 20100239548
    Abstract: The present invention relates to improved autologous T cell vaccines and improved methods for their production. The invention is also directed to methods for treating autoimmune diseases such as multiple sclerosis or rheumatoid arthritis using autologous T cell vaccines. The invention further directed to the diagnosis of T associated diseases.
    Type: Application
    Filed: February 23, 2010
    Publication date: September 23, 2010
    Applicant: Baylor College of Medicine
    Inventor: Jingwu Z. Zang
  • Isolation and identification of T cells
    Patent number: 7695713
    Abstract: The present invention relates to improved autologous T cell vaccines and improved methods for their production. The invention is also directed to methods for treating autoimmune diseases such as multiple sclerosis or rheumatoid arthritis using autologous T cell vaccines. The invention is further directed to the diagnosis of T cell associated diseases.
    Type: Grant
    Filed: August 6, 2003
    Date of Patent: April 13, 2010
    Assignee: Baylor College of Medicine
    Inventor: Jingwu Z. Zang
  • Autologous T-cell vaccines materials and methods
    Patent number: 7658926
    Abstract: The present invention relates to improved autologous T cell vaccines and methods for their production. The invention is also directed to methods for treating T cell associated diseases such as multiple sclerosis are rheumatoid arthritis using autologous T cell vaccines.
    Type: Grant
    Filed: September 14, 2001
    Date of Patent: February 9, 2010
    Assignee: Opexa Pharmaceuticals, Inc.
    Inventor: Jingwu Z. Zang
  • Isolation and Identification of Cross-Reactive T Cells
    Publication number: 20090311229
    Abstract: Cross-reactive T cells recognizing both MBP93-105 and HHV-61-13 peptides represent a significant subset of T cells with some degree of TCR degeneracy. It appears that the recognition of the cross-reactive T cells has a less stringent requirement for the flanking residues of the two peptides. In contrast, these flanking residues are critical for the T cell recognition of mono-specific T cells. The association between HHV-6 and autoreactive immune responses to MBP indicates that cross-reactive T cells, peptides from the V-D-J region of the T cell receptor from autoreactive T cells, and antiviral agents may prevent or treat MS.
    Type: Application
    Filed: August 19, 2009
    Publication date: December 17, 2009
    Inventor: Jingwu Z. Zang